Deutsche Bank’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.3M Buy
932,090
+2,568
+0.3% +$38.5K ﹤0.01% 992
2025
Q4
$14.4M Buy
929,522
+756
+0.1% +$10.1K ﹤0.01% 977
2025
Q3
$9.58M Hold
928,766
﹤0.01% 1065
2025
Q2
$10.3M Buy
928,766
+4,492
+0.5% +$56.2K ﹤0.01% 988
2025
Q1
$11.4M Buy
924,274
+511,662
+124% +$6.4M ﹤0.01% 977
2024
Q4
$4.62M Buy
412,612
+356
+0.1% +$3.1K ﹤0.01% 1369
2024
Q3
$2.87M Sell
412,256
-241,429
-37% -$1.77M ﹤0.01% 1550
2024
Q2
$4.94M Buy
+653,685
New +$6.6M ﹤0.01% 1254
2022
Q2
Sell
-3,857
Closed -$32K 4261
2022
Q1
$32K Sell
3,857
-460
-11% -$3.97K ﹤0.01% 3961
2021
Q4
$44K Buy
4,317
+230
+6% +$2.99K ﹤0.01% 3991
2021
Q3
$65K Sell
4,087
-46
-1% -$966 ﹤0.01% 4045
2021
Q2
$98K Buy
+4,133
New +$95.9K ﹤0.01% 4154

Other funds holding NPCE

Deutsche Bank's NPCE Position: Q1 2026 in Review

Deutsche Bank increased its Neuropace (NPCE) stake by 0.28% in Q1 2026, buying an estimated $38.5K and bringing the position to 932,090 shares worth $12.3M. The position accounts for ﹤0.01% of the portfolio, ranked #992.

Deutsche Bank first reported a position in NPCE in Q2 2021 and has held it in 12 quarters since. The position peaked at $14.4M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Deutsche Bank held 932,090 shares of Neuropace worth $12.3M as of Q1 2026.
  • Deutsche Bank bought 2,568 Neuropace shares in Q1 2026, an estimated $38.5K.
  • Neuropace made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #992 holding.
  • Deutsche Bank first reported a position in Neuropace in Q2 2021 and has held it in 12 quarters since.
  • Deutsche Bank's Neuropace position peaked at $14.4M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.